AMGN · News · 20260910N
IMDELLTRA Lung Cancer Results
AMGEN INC · 2026-09-10 · Importance 34 · Surprise 42 · In source text
Amgen and AstraZeneca reported that the IMDELLTRA-Imfinzi combination produced a survival benefit in first-line extensive-stage small-cell lung cancer. The result could expand IMDELLTRA’s use beyond its current treatment setting and increase its addressable lung-cancer market. The development also strengthens the commercial positioning of the combination for patients and oncology prescribers seeking first-line treatment options.
Key facts
- The article covers positive Phase 3 trial results for Imdelltra. source
- Zacks reported that Amgen and AstraZeneca's Imdelltra-Imfinzi combo shows survival benefits in first-line ES-SCLC. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | probable | — | The article covers positive Phase 3 trial results for Imdelltra. |